Medicare Enrolled
Dr. Akbar Rizvi, MD
Hematology & Oncology · Mckinney, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Rizvi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rizvi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Rizvi
Dr. Akbar Rizvi is a hematology & oncology specialist in Mckinney, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Rizvi performed 94,092 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Rizvi received a total of $5,754 from 60 pharmaceutical and/or device companies across 283 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rizvi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 9% volume in TX
$5,754 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗94,092
Medicare services
Top 9% in TX for hematology & oncology
Not available
Unique patients (not deduplicated)
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
34,600 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
19,800 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 13,300 | $43 | $137 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,952 | $0 | $1 |
| Immune globulin infusion (Octagam) This procedure involves the administration of immune globulin medication directly into a vein. It is provided in a non-lyophilized liquid form. |
3,850 | $34 | $234 |
| Denosumab injection (Prolia/Xgeva) | 2,040 | $18 | $66 |
| Injection, granisetron hydrochloride, 100 mcg | 1,880 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 1,725 | $3 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,590 | $1 | $114 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,527 | $8 | $36 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,423 | $93 | $368 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
1,217 | $10 | $64 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,162 | $8 | $20 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
826 | $2 | $13 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
820 | $12 | $108 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
555 | $97 | $707 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
368 | $58 | $247 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
292 | $47 | $313 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
290 | $22 | $157 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
202 | $7 | $431 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
196 | $0 | $36 |
| Iron level test | 173 | $6 | $27 |
| Iron binding capacity test A blood test that measures the amount of iron in the blood and the blood's ability to bind and transport iron. |
173 | $9 | $35 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
171 | $13 | $60 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
152 | $2 | $300 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
141 | $1 | $7 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
137 | $49 | $344 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
136 | $11 | $96 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
116 | $21 | $161 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
109 | $123 | $500 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
97 | $19 | $99 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
97 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
97 | $6 | $34 |
| Reticulated platelet measurement A blood test that measures the level of young, newly formed platelets in the body. |
90 | $35 | $143 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
89 | $15 | $94 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
76 | $53 | $250 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
74 | $109 | $565 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
72 | $16 | $100 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
66 | $2 | $19 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
52 | $1 | $8 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
50 | $125 | $694 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
49 | $18 | $114 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 48 | $90 | $657 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
44 | $92 | $470 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
42 | $1,090 | $4,802 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
31 | $1 | $19 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
29 | $10 | $75 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
27 | $59 | $348 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 20 | $20 | $128 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
19 | $28 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
5.7% high complexity
86.8% medium
7.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$5,754
Total received (2018-2024)
Avg $822/year across 7 years
Top 41% in TX for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
283
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,978
2023
$1,371
2022
$485
2021
$164
2020
$269
2019
$616
2018
$869
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$744
PFIZER INC.
$162
Janssen Biotech, Inc.
$118
AstraZeneca Pharmaceuticals LP
$109
SANOFI-AVENTIS U.S. LLC
$100
Incyte Corporation
$77
Daiichi Sankyo Inc.
$75
Medtronic, Inc.
$58
Gilead Sciences, Inc.
$51
ARRAY BIOPHARMA INC
$45
Astellas Pharma US Inc
$45
Alnylam Pharmaceuticals Inc.
$45
Sirtex Medical Inc
$36
Janssen Pharmaceuticals, Inc
$31
Inari Medical, Inc.
$28
Kite Pharma, Inc.
$25
Genmab U.S., Inc.
$23
EMD Serono, Inc.
$23
Kyowa Kirin, Inc.
$21
ABBVIE INC.
$21
Secura Bio, Inc.
$20
E.R. Squibb & Sons, L.L.C.
$19
Acrotech Biopharma Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
GlaxoSmithKline, LLC.
$18
ADC Therapeutics America, Inc.
$16
GENZYME CORPORATION
$16
Celgene Corporation
$15
Top 3 companies account for 51.8% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,060
PFIZER INC.
$494
AstraZeneca Pharmaceuticals LP
$310
E.R. Squibb & Sons, L.L.C.
$285
Genentech USA, Inc.
$261
Janssen Biotech, Inc.
$223
Medtronic, Inc.
$221
GENZYME CORPORATION
$173
Gilead Sciences, Inc.
$156
Incyte Corporation
$145
Merck Sharp & Dohme Corporation
$145
Celgene Corporation
$138
Daiichi Sankyo Inc.
$122
Lilly USA, LLC
$115
PharmaEssentia USA Corporation
$111
Seagen Inc.
$105
SANOFI-AVENTIS U.S. LLC
$100
Janssen Pharmaceuticals, Inc
$81
Regeneron Healthcare Solutions, Inc.
$81
Octapharma USA, Inc.
$65
EMD Serono, Inc.
$64
Acrotech Biopharma LLC
$64
Astellas Pharma US Inc
$63
ARRAY BIOPHARMA INC
$62
Sirtex Medical Inc
$55
Kite Pharma, Inc.
$54
Amgen Inc.
$54
Merck Sharp & Dohme LLC
$54
TerSera Therapeutics LLC
$54
Karyopharm Therapeutics Inc.
$49
Clovis Oncology, Inc.
$49
Alnylam Pharmaceuticals Inc.
$45
Genmab U.S., Inc.
$43
AVEO Pharmaceuticals, Inc.
$40
Ipsen Biopharmaceuticals, Inc
$40
Boehringer Ingelheim Pharmaceuticals, Inc.
$38
Stemline Therapeutics Inc.
$38
ADC Therapeutics America, Inc.
$35
Pharmacyclics LLC, An AbbVie Company
$32
Inari Medical, Inc.
$28
Global Blood Therapeutics, Inc.
$26
Sobi, Inc
$26
Seattle Genetics, Inc.
$24
Epizyme, Inc.,
$24
MorphoSys, US Inc.
$23
Rigel Pharmaceuticals, Inc.
$23
TESARO, Inc.
$23
Eisai Inc.
$23
Kyowa Kirin, Inc.
$21
ABBVIE INC.
$21
Secura Bio, Inc.
$20
Blueprint Medicines Corporation
$20
Acrotech Biopharma Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$19
GlaxoSmithKline, LLC.
$18
MEDIVATION FIELD SOLUTIONS LLC
$17
Myriad Genetic Laboratories, Inc.
$17
Exelixis Inc.
$16
Mylan Institutional Inc.
$12
Arbor Pharmaceuticals, Inc.
$11
Top 3 companies account for 32.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · AYVAKIT · Abraxane · Alecensa · Avastin · BELEODAQ · BESREMI · BOSULIF · Bavencio · CALQUENCE · CARVYKTI · COPIKTRA · CREON · CT THROMBECTOMY SYSTEM KIT · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · ELIQUIS · ELREXFIO · EMPLICITI · ENJAYMO · Enhertu · Epkinly · Erleada · FOTIVDA · GAZYVA · GILOTRIF · GIVLAARI · Gliadel · IBRANCE · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KYPHON EXPRESS II KYPHOPAK TRAY · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MYLOTARG · Nplate · Nubeqa · OCTAGAM · OJJAARA · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · OXBRYTA · Ogivri · Orserdu · PADCEV · PIQRAY · PLUVICTO · PRECISETUMOR · PROMACTA · Padcev · Perjeta · Pomalyst · Poteligeo · REBLOZYL · RYBREVANT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · Somatuline Depot · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TEPMETKO · TUKYSA · Trodelvy · VARUBI · VENCLEXTA · Vanflyta · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XPOVIO · XTANDI · Yescarta · ZEJULA · ZOLADEX · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
25
County median income
$117,588
Nearest hospital to ZIP centroid (approximate)
BAYLOR SCOTT AND WHITE MEDICAL CENTER MCKINNEY
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Rizvi is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Rizvi experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Rizvi performed 34,600 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Rizvi receive payments from pharmaceutical companies?
Yes. Dr. Rizvi received a total of $5,754 from 60 companies across 283 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rizvi's costs compare to other hematology & oncology specialists in Mckinney?
Dr. Rizvi's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rizvi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Mckinney
Browse hematology & oncology specialists in Mckinney ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology